Citius Pharmaceuticals (NASDAQ:CTXR) Shares to Reverse Split on Tuesday, November 26th

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR)’s stock is scheduled to reverse split before the market opens on Tuesday, November 26th. The 1-25 reverse split was announced on Friday, November 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, November 25th.

Citius Pharmaceuticals Stock Performance

NASDAQ:CTXR traded down $0.03 during trading hours on Friday, reaching $0.13. The stock had a trading volume of 16,080,649 shares, compared to its average volume of 1,653,007. The stock has a market capitalization of $24.18 million, a PE ratio of -0.54 and a beta of 1.66. Citius Pharmaceuticals has a 52 week low of $0.11 and a 52 week high of $1.07. The company has a 50 day moving average price of $0.40 and a two-hundred day moving average price of $0.58.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Citius Pharmaceuticals in a report on Tuesday, November 12th.

Institutional Trading of Citius Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Armistice Capital LLC purchased a new stake in Citius Pharmaceuticals in the second quarter worth about $5,928,000. Geode Capital Management LLC boosted its stake in shares of Citius Pharmaceuticals by 14.1% during the third quarter. Geode Capital Management LLC now owns 1,878,953 shares of the company’s stock valued at $941,000 after purchasing an additional 232,656 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Citius Pharmaceuticals during the second quarter valued at approximately $118,000. Cubist Systematic Strategies LLC purchased a new stake in Citius Pharmaceuticals during the second quarter worth $69,000. Finally, Vanguard Group Inc. boosted its position in Citius Pharmaceuticals by 1.5% during the 1st quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock valued at $6,286,000 after acquiring an additional 104,889 shares in the last quarter. Institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.